ERBB2 and non-small cell lung carcinoma: For this reason, the subgroup of patients with HER2-overexpressing NSCLC who specifically have CNS metastases, after further study, may be uniquely positioned to derive benefit from TDXd compared to alternative agents that possess poor intracranial activity